These findings suggest that adults with type 2 diabetes in the highest quartile of OOP costs were 13% and 20% less likely to initiate a GLP-1 RA or SGLT2 inhibitor, respectively, when compared with those in the lowest quartile of OOP costs. Here, SLC5A2 is linked to type 2 diabetes mellitus.